Renovaro Biosciences is a biotechnology company engaged in developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers, and potentially to treat or cure diseases such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. Co.'s product candidates include: RENB-DC-11 for the indication of dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX for the indication of dendritic cell therapeutic vaccine for other solid tumors; RENB-HV-12 for the indication of HIV therapeutic vaccine; and RENB-HV-01 for the indication of HIV autologous transplant and HBV gene therapy. The RENB average annual return since 2018 is shown above.
The Average Annual Return on the RENB average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RENB average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RENB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free RENB Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
